NONOF
Price
$55.67
Change
-$0.14 (-0.25%)
Updated
Aug 27 closing price
Capitalization
247.11B
SLXN
Price
$7.74
Change
+$0.48 (+6.61%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
5.66M
Interact to see
Advertisement

NONOF vs SLXN

Header iconNONOF vs SLXN Comparison
Open Charts NONOF vs SLXNBanner chart's image
Novo-Nordisk A/S
Price$55.67
Change-$0.14 (-0.25%)
Volume$114.94K
Capitalization247.11B
Silexion Therapeutics
Price$7.74
Change+$0.48 (+6.61%)
Volume$300
Capitalization5.66M
NONOF vs SLXN Comparison Chart in %
Loading...
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NONOF vs. SLXN commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NONOF is a StrongBuy and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (NONOF: $55.67 vs. SLXN: $7.74)
Brand notoriety: NONOF and SLXN are both not notable
NONOF represents the Pharmaceuticals: Major, while SLXN is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: NONOF: 33% vs. SLXN: 35%
Market capitalization -- NONOF: $247.11B vs. SLXN: $5.66M
NONOF [@Pharmaceuticals: Major] is valued at $247.11B. SLXN’s [@Biotechnology] market capitalization is $5.66M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $100.52B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $89.11B. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NONOF’s FA Score shows that 2 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).

  • NONOF’s FA Score: 2 green, 3 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, NONOF is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NONOF’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 5 bullish TA indicator(s).

  • NONOF’s TA Score: 4 bullish, 5 bearish.
  • SLXN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SLXN is a better buy in the short-term than NONOF.

Price Growth

NONOF (@Pharmaceuticals: Major) experienced а +3.57% price change this week, while SLXN (@Biotechnology) price change was +13.75% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.28%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +11.94%.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.11%. For the same industry, the average monthly price growth was +20.33%, and the average quarterly price growth was +29.99%.

Industries' Descriptions

@Pharmaceuticals: Major (-1.28% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

@Biotechnology (+2.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NONOF($247B) has a higher market cap than SLXN($5.66M). NONOF YTD gains are higher at: -35.190 vs. SLXN (-74.345). NONOF has higher annual earnings (EBITDA): 154B vs. SLXN (-17.81M). NONOF has more cash in the bank: 18.9B vs. SLXN (3.47M). SLXN has less debt than NONOF: SLXN (3.7M) vs NONOF (99.3B). NONOF has higher revenues than SLXN: NONOF (312B) vs SLXN (0).
NONOFSLXNNONOF / SLXN
Capitalization247B5.66M4,364,729%
EBITDA154B-17.81M-864,489%
Gain YTD-35.190-74.34547%
P/E Ratio14.59N/A-
Revenue312B0-
Total Cash18.9B3.47M545,297%
Total Debt99.3B3.7M2,685,235%
FUNDAMENTALS RATINGS
NONOF: Fundamental Ratings
NONOF
OUTLOOK RATING
1..100
2
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
PROFIT vs RISK RATING
1..100
81
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NONOFSLXN
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 1 day ago
10%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 1 day ago
27%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 1 day ago
30%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
27%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 1 day ago
52%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 1 day ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 8 days ago
76%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
62%
Bullish Trend 4 days ago
38%
Aroon
ODDS (%)
Bearish Trend 2 days ago
69%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MGPI29.771.12
+3.91%
MGP Ingredients
SDOT0.940.02
+1.70%
Sadot Group Inc
HURC17.960.21
+1.18%
Hurco Companies
CRBG34.97-0.01
-0.03%
Corebridge Financial
SOC28.36-0.04
-0.14%
Sable Offshore Corp

NONOF and

Correlation & Price change

A.I.dvisor indicates that over the last year, NONOF has been closely correlated with NVO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NONOF jumps, then NVO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NONOF
1D Price
Change %
NONOF100%
-0.25%
NVO - NONOF
70%
Closely correlated
+1.99%
LABFF - NONOF
23%
Poorly correlated
N/A
IMRN - NONOF
22%
Poorly correlated
+1.43%
QSI - NONOF
21%
Poorly correlated
-0.85%
VRTX - NONOF
21%
Poorly correlated
+0.49%
More